Breast cancer results = OUTSTANDING! Pancreatic cancer results = lower ECOG results looks good. Second line NSCLC = GOING INTO PHASE III!
This is what potential partners have been looking at for some time now. They may also be looking at the front line NSCLC and liver cancer data. Anyone care to estimate market potential in first and second line NSCLC, breast cancer, pancreatic and liver cancer?
News 
Market Data 
Discover 
